BALDR: A Web-based platform for informed comparison and prioritization of biomarker candidates for type 2 diabetes mellitus

Novel biomarkers are key to addressing the ongoing pandemic of type 2 diabetes mellitus. While new technologies have improved the potential of identifying such biomarkers, at the same time there is an increasing need for informed prioritization to ensure efficient downstream verification. We have bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lundgaard, Agnete T., Burdet, Frédéric, Siggaard, Troels, Westergaard, David, Vagiaki, Danai, Cantwell, Lisa, Röder, Timo, Vistisen, Dorte, Sparsø, Thomas, Giordano, Giuseppe N., Ibberson, Mark, Banasik, Karina, Brunak, Søren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Software
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464978/
https://www.ncbi.nlm.nih.gov/pubmed/37590326
http://dx.doi.org/10.1371/journal.pcbi.1011403
Descripción
Sumario:Novel biomarkers are key to addressing the ongoing pandemic of type 2 diabetes mellitus. While new technologies have improved the potential of identifying such biomarkers, at the same time there is an increasing need for informed prioritization to ensure efficient downstream verification. We have built BALDR, an automated pipeline for biomarker comparison and prioritization in the context of diabetes. BALDR includes protein, gene, and disease data from major public repositories, text-mining data, and human and mouse experimental data from the IMI2 RHAPSODY consortium. These data are provided as easy-to-read figures and tables enabling direct comparison of up to 20 biomarker candidates for diabetes through the public website https://baldr.cpr.ku.dk.

Ejemplares similares